Calcimedica Inc (CALC)

$4.44

+0.03

(+0.68%)

Market is closed - opens 7 PM, 15 Apr 2024

Insights on Calcimedica Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 47.7% return, outperforming this stock by 17.5%

Performance

  • $4.32
    $4.59
    $4.44
    downward going graph

    2.7%

    Downside

    Day's Volatility :5.88%

    Upside

    3.27%

    downward going graph
  • $1.75
    $8.59
    $4.44
    downward going graph

    60.59%

    Downside

    52 Weeks Volatility :79.63%

    Upside

    48.31%

    downward going graph

Returns

PeriodCalcimedica IncIndex (Russel 2000)
3 Months
30.21%
0.0%
6 Months
101.82%
0.0%
1 Year
30.21%
-0.7%
3 Years
-29.86%
-21.3%

Highlights

Market Capitalization
45.2M
Book Value
$2.14
Earnings Per Share (EPS)
82.57
PE Ratio
0.05
Wall Street Target Price
16.38
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-157.2%
Return On Equity TTM
-2359.2%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-20.6M
Diluted Eps TTM
82.57
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.29
EPS Estimate Next Year
-2.2
EPS Estimate Current Quarter
-0.87
EPS Estimate Next Quarter
-0.73

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Calcimedica Inc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
7
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 268.92%

Current $4.44
Target $16.38

Technicals Summary

Sell

Neutral

Buy

Calcimedica Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Calcimedica Inc
Calcimedica Inc
1.83%
101.82%
30.21%
-29.86%
-29.86%
Moderna, Inc.
Moderna, Inc.
1.62%
14.36%
-33.07%
-34.3%
306.89%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-5.67%
7.24%
9.09%
88.02%
140.93%
Novo Nordisk A/s
Novo Nordisk A/s
-7.48%
23.09%
47.7%
252.97%
394.48%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-2.99%
6.03%
18.9%
82.63%
117.3%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Calcimedica Inc
Calcimedica Inc
0.05
0.05
NA
-2.29
-23.59
-1.57
NA
2.14
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.2
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.28
26.28
1.51
44.87
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.32
46.32
2.38
3.35
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.64
28.64
0.54
16.78
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Calcimedica Inc
Calcimedica Inc
Buy
$45.2M
-29.86%
0.05
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$41.0B
306.89%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$100.2B
140.93%
26.28
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$565.1B
394.48%
46.32
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$102.8B
117.3%
28.64
36.68%

Company Information

calcimedica is dedicated to the discovery and development of novel small molecule drugs for the treatment of autoimmune disorders, organ transplant rejection, and other immune diseases.

Organization
Calcimedica Inc
Employees
14
CEO
Dr. A. Rachel Leheny Ph.D.
Industry
Miscellaneous

FAQs